- Home
- TTGT vs AVTX Comparison
TTGT vs AVTX Comparison
Compare TTGT & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TTGT | AVTX |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 344.2M | 328.4M |
| IPO Year | 2024 | 2015 |
Fundamental Metrics
Financial Performance| Metric | TTGT | AVTX |
|---|---|---|
| Price | $4.26 | $14.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $10.75 | ★ $40.57 |
| AVG Volume (30 Days) | 305.0K | ★ 890.5K |
| Earning Date | 03-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | $4.45 | N/A |
| Revenue Next Year | $2.75 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $3.41 | $3.39 |
| 52 Week High | $9.00 | $20.72 |
Technical Indicators
Market Signals| Indicator | TTGT | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.79 | 46.69 |
| Support Level | $3.49 | $13.38 |
| Resistance Level | $4.75 | $16.40 |
| Average True Range (ATR) | 0.32 | 1.35 |
| MACD | 0.04 | -0.10 |
| Stochastic Oscillator | 62.20 | 21.52 |
Price Performance
Historical ComparisonAbout TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.